Binding proteins specific for ha-1h and uses thereof

A protein-binding and specific technology, applied in peptide/protein components, animal/human proteins, immunoglobulin superfamily, etc., can solve the problems of lack of in vivo persistence of T cells and in vivo anti-leukemia reactivity

Pending Publication Date: 2021-07-30
ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has been previously shown in phase I clinical studies that in vitro cultured HA-1-specific T cells deri

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Binding proteins specific for ha-1h and uses thereof
  • Binding proteins specific for ha-1h and uses thereof
  • Binding proteins specific for ha-1h and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0443] TCR gene transfer is an attractive strategy to modify T cells with well-defined specificities in a short period of time. Recently, the effectiveness of TCR transfer was demonstrated in melanoma or synoviocyte sarcoma patients treated with TCR-modified autologous T cells. In order to engineer T cells capable of selective GvL without GvHD, we prefer to transfer HA-1-TCR. To expand the applicability of acquired T cell therapy in hematological malignancies, we initiated a clinical study using HA-1-TCR-transferred virus-specific T cells. We sequenced the TCR chains of three HA-1-specific T cell clones, M2, M7 and FK47.83 (Table 4).

[0444]

[0445]

[0446] Table 4. HA-1-TCR sequences of clones M2, M7 and FK47.83.

[0447] As previously described, we again observed that all three HA-1-specific T cell clones expressed a β chain with a similar V region (TRBV7-9) (4). A LZRS retroviral construct encoding the TCR alpha and beta chains of M2 and M7 was prepa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Novel nucleic acid compositions, vectors, modified cells and pharmaceutical compositions are provided that are useful for treating or preventing a relapse of a haematological malignancy after allogeneic stem cell transplantation (allo-SCT) in a HLA-A*0201 positive human subject. Corresponding methods and uses are also provided.

Description

technical field [0001] The present invention provides novel nucleic acid compositions, vector systems, modified cells and pharmaceutical compositions useful for the treatment or prevention of hematological disorders after allogeneic stem cell transplantation (allo-SCT) in HLA-A*0201-positive human subjects recurrence of malignancy. Corresponding methods and uses are also provided. Background technique [0002] Hematological malignancies are cancers that affect the blood and lymphatic system. Cancer may start in blood-forming tissues, such as the bone marrow, or in cells of the immune system. Patients with hematologic malignancies can be successfully treated with human leukocyte antigen (HLA)-matched allogeneic stem cell transplantation (allo-SCT). To reduce the development of graft-versus-host disease (GvHD), donor T cells can be depleted from stem cell grafts and preemptively readministered after allo-SCT. Although this two-step procedure of T-cell-depleted allo-SCT and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/725C07K14/74A61K35/17C12N5/0783
CPCC07K14/7051C07K14/70539A61K35/17C12N5/0636C12N15/85A61K48/00A61K38/00A61P35/00C12N2510/00
Inventor 米丽娅姆·H·M·海姆斯凯克J·H·弗雷德里克·福尔肯伯格
Owner ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap